

## Effect of hypertension and its reverse on serum nitric oxide concentration and vascular permeability in two-kidney one-clip hypertensive rats

Majid Khazaei<sup>1</sup>, Mohammad Zarei<sup>2</sup>, Mohammad R. Sharifi<sup>1</sup> and Ali A. Pourshanazari<sup>1</sup>

<sup>1</sup> Department of Physiology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

<sup>2</sup> Department of Physiology, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran

**Abstract.** The aim of this study was to evaluate the effect of hypertension and its reverse on serum nitric oxide (NO) concentration and endothelial permeability in two-kidney one-clip (2K1C) hypertensive rats. 28 male Wistar rats were divided into four groups: 1) 2K1C for 12 weeks; 2) sham-clipped for 12 weeks; 3) 2K1C for 12 weeks and unclipped for 12 weeks; 4) sham-clipped for 12 weeks and unclipped for 12 weeks. Blood samples were taken before experiment, 12<sup>th</sup> week and 24<sup>th</sup> week (in groups 3 and 4). Coronary vascular and aortic endothelial permeability were determined by extravasation of Evans blue dye method. Serum NO level was significantly lower in hypertensive group compare with sham group ( $4.21 \pm 1.28$  vs.  $9.47 \pm 1.34$   $\mu\text{mol/l}$ , respectively). Reversal of hypertension did not improve serum NO concentration in 2K1C group ( $4.21 \pm 1.28$  vs.  $4.32 \pm 1.34$   $\mu\text{mol/l}$ ). Coronary vascular and aortic endothelial permeability were not different between hypertensive and normotensive groups and reversal of hypertension did not alter endothelial permeability. Lower serum NO concentration in 2K1C hypertensive rats even after reversal of hypertension suggested that in addition to NO, other mechanisms could be involved in surgical reversal of hypertension. Hypertension and its reverse did not change endothelial permeability at least in this model of hypertension.

**Key words:** Hypertension — Two-kidney one-clip — Nitric oxide — Permeability — Endothelium

**Abbreviations:** 2K1C, two-kidney one-clip; EB, Evans blue; EP, endothelial permeability; PRA, plasma renin activity; SBP, systolic blood pressure.

### Introduction

Hypertensive patients are at particular risk of cardiovascular complications and stroke, possibly related to endothelial dysfunction (Viazzzi et al. 2008). Endothelium has an essential role in control of vascular function and homeostasis. It is believed that endothelial dysfunction is a preclinical stage of atherosclerosis processes and considered as a target for cardiovascular risk factors (Feletou and Vanhoutte 2006). Endothelial dysfunction during hypertension leads to dysregulation of many important vascular functions including

platelet aggregation or leukocyte adhesion (Khazaei et al. 2008; Versari et al. 2009).

The vascular endothelium is capable of synthesizing nitric oxide (NO) from L-arginine. NO as a biological messenger and effector molecule is known to be involved in several physiological and pathophysiological processes in various organ systems (Bauer and Sotnikova 2010) and had been implicated in the pathogenesis of several diseases including hypertension (Hermann et al. 2006; Torok 2008). Studies have provided evidences that impairment of NO production accounts for the abnormalities in vascular function in hypertension in animals and humans (Hermann et al. 2006; Bian et al. 2008; Torok 2008). Several studies have shown that NO is closely involved in the regulation of vascular tone and systemic blood pressure. In addition, NO has several antiatherosclerotic

Correspondence to: Majid Khazaei, Department of Physiology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran  
E-mail: Khazaei@med.mui.ac.ir

properties including inhibition of platelet aggregation, leukocyte adhesion to endothelial cells, smooth muscle cell proliferation and migration (Ross 1999; Kawashima and Yokoyama 2004).

Hypertension is a risk factor for cardiovascular disease and recent studies suggested that increased endothelial permeability may have a role in development of end organ damage (Viazzi et al. 2008). Furthermore, it is believed that endothelial cell injury is responsible for the development of atherosclerosis (Luscher 1994; Torok 2008). Changes in injured endothelium lead to disruption of its permeability characteristics and increase retaining of oxidised LDL in subintimal space which initiates a vicious cycle for atherosclerosis (Ross 1993, 1999). Therefore, we hypothesize that chronic hypertension alters vascular endothelial permeability and serum NO concentration as a well known marker of endothelial function in two-kidney one-clip (2K1C) hypertensive rats. 2K1C hypertensive model is a well known model of hypertension. Increased activity of renin-angiotensin-aldosterone system is responsible for rising blood pressure in this model especially in first 6 weeks (Martinez-Maldonado 1991; Nystrom et al. 2002) and subsequent changes of vascular structure is important in maintenance of hypertension (Martinez-Maldonado 1991). In the second part of this study, we tried to assess changes of endothelial permeability and serum NO concentration after surgical reversal of hypertension to evaluate whether the changes are reversible after blood pressure reduction.

## Materials and Methods

### *Animals and experimental groups*

28 male Wistar rats with an initial body weight of 180–200 g were purchased from Pasteur Institute of Iran. The animals were housed in cages (3 or 4 per cage) at 22–25°C with 12 h light/dark cycle. The animals were randomly divided into two groups: sham-clipped and 2K1C hypertensive rats. After surgery, each group was divided into two subgroups: clipping and unclipping groups. The experimental groups were as follow:

- group 1: 2K1C for 12 weeks ( $n = 7$ )
- group 2: sham-clipped for 12 weeks ( $n = 7$ )
- group 3: 2K1C for 12 weeks and unclipped for 12 weeks ( $n = 7$ )
- group 4: sham-clipped for 12 weeks and unclipped for 12 weeks ( $n = 7$ ).

Blood samples were taken from all animals on pre-clipping, 12<sup>th</sup> week and 24<sup>th</sup> week (in groups 3 and 4). Samples were centrifuged and plasma and serums were kept in –70°C for further analysis. All procedures were conducted and approved from ethical committee of Isfahan University of

Medical Sciences in accordance with guideline for care and use of laboratory animals.

### *Preparation of 2K1C hypertensive rats*

Rats were anesthetized with intraperitoneally injection of ketamine hydrochloride (60 mg/kg) and xylazine (7.5 mg/kg) and underwent left renal artery constriction with a silver clip (internal gap of 0.20 mm) as described previously (Kunes 1993; Diekmann et al. 2000; Nystrom et al. 2002). In sham-clipped group, the same procedure was done without using silver clip. After closing the wound, penicillin G (25 000 U i.m) was injected. All rats were fed with commercial rat chow (Pasteur Institute, Iran) and allowed free access to tap water during the experiments.

### *Reversal of 2K1C hypertension*

In groups 3 and 4, unclipping was carried out on 12<sup>th</sup> weeks (12 weeks after clipping). For this purpose, the rats were anesthetized. Through a flank incision, the clipped left renal artery was exposed and fibrous tissues surrounding the clip and renal artery were carefully dissected. Then, the clip was removed gently. In sham-unclipped group, the same procedure was done without removing the clip.

### *Blood pressure measurement*

During the study, systolic blood pressure (SBP) was measured under conscious conditions twice a week by tail-cuff method with non-invasive blood pressure controller PowerLab software (ADInstruments Company, USA). Before sacrificing rats, direct blood pressure was also measured by cannulation of the carotid artery (PE-50) using an invasive blood pressure controller PowerLab software.

### *Measurement of serum NO concentration*

Serum NO concentrations were measured by Griess reagent system (Promega Corporation, Madison, USA), using available reagents as previously described (Khazaei and Nematbakhsh 2006). In brief, serums were added into wells (96-well enzymatic assay plate). Sulfanilamide solution was added to all collected samples and then *N*-1-naphthylethylenediamine dihydrochloride under acidic conditions was added. The absorbance was detected by a microplate reader in 520–550 nm wavelengths. The samples NO concentration was determined by comparison to nitrite standard curve. The limit detection was 2.5  $\mu$ M nitrite.

### *Measurement of endothelial permeability*

Coronary vascular and aortic endothelial permeability were determined by extravasation of Evans blue (EB) dye method

as previously described (Hulthen et al. 1996; Khazaei and Nematbakhsh 2004). First, EB (diluted in normal saline; 20 mg/ml) was injected through the carotid artery cannula. After 20 min, rats were sacrificed. Heart and aorta (ascending aorta to the origin of renal arteries branches) were isolated and cleaned from surrounding connective tissues. Then, they were weighed and put into formamide solution overnight at room temperature for EB dye extraction. The extracted amount of EB in formamide solution was determined by spectrophotometer (Secomam, France) at 620 nm wavelength. The results were plotted on standard of EB in 0.2 to 10  $\mu\text{g/ml}$  formamide. Concentration of EB in these tissues was expressed in  $\mu\text{g/g}$  wet weight ( $\mu\text{g/g}$  ww) tissue.

#### Plasma renin activity

Plasma renin activity (PRA) was measured using I-125 Angiotensin I generation. Angiotensin I coated-tube radioimmunoassay was performed in two aliquots of the same sample, one incubated at 37°C for generation and one non-incubated. PRA was calculated as nanogram angiotensin I generated/ml/h (Renctk P2721, DiaSorin Biomedica Diagnostic Division RIA kit, Italy). The PRA assay sensitivity was 0.13 ng/ml; intra- and interassay coefficients of variation were 7.5 and 7.7%, respectively.


#### Statistical analysis

Data are expressed as mean  $\pm$  SEM. Comparison of data in the same group before and after intervention were made using the paired *t*-test. Comparisons of data among groups were carried out using one-way ANOVA.  $p < 0.05$  was considered statistically significant.

## Results

#### Blood pressure

SBP values after clipping and unclipping in all experimental groups are shown in Fig. 1 which illustrates higher SBP of 2K1C group compare to sham-clipped group ( $162.84 \pm 3.79$



**Figure 1.** Systolic blood pressure values in pre-clipping, post-clipping and unclipping rats. \*  $p < 0.05$  vs. other groups.

vs.  $104.16 \pm 3.96$  mmHg;  $p < 0.05$ ). After unclipping, SBP of 2K1C hypertensive rats significantly reduced and reached to sham-unclipped level ( $162.84 \pm 3.79$  vs.  $118.4 \pm 4.42$  mmHg,  $p < 0.05$ ).

#### PRA measurement

PRA levels were measured in 2K1C hypertensive rats and are shown in Table 1. PRA level was significantly higher in 2K1C after clipping and reduced after unclipping ( $p < 0.05$ ).


#### Serum NO concentration

Fig. 2 illustrates serum NO concentration in sham and 2K1C hypertensive rats before and after clipping and unclipping. There was no significant difference in serum NO concentration in pre-clipping between groups ( $p > 0.05$ ). After clipping, serum NO concentration in 2K1C hypertensive rats was

**Table 1.** Plasma renin activity (PRA) values in 2K1C hypertensive rats

Rats	<i>n</i>	PRA (ng/ml/h)
Pre-clipping	11	3.14 $\pm$ 0.18
Post-clipping	14	5.70 $\pm$ 0.24*
Unclipping	7	3.32 $\pm$ 0.16

Data are expressed as mean  $\pm$  S.E. \*  $p < 0.05$  compare to other groups.



**Figure 2.** Serum NO concentration in sham and 2K1C hypertensive rats before and after clipping and unclipping ( $n = 7$  each group). \*  $p < 0.05$  vs. sham group.

decreased and it was significantly lower than sham-clipped group ( $p < 0.05$ ). Unclipping and surgical reversal of hypertension in 2K1C group did not improve serum NO level and it was lower than sham-unclipped group ( $p < 0.05$ ).

#### Vascular endothelial permeability

Vascular endothelial permeability of aorta (expressed as quantitative extravasations of EB) in 2K1C hypertensive group was lower than sham-clipped group, although it was not statistically significant ( $p > 0.05$ ) (Table 2). Unclipping didn't alter aortic endothelial permeability in 2K1C group ( $p > 0.05$ ). Also, vascular endothelial permeability of coronary circulation wasn't different between 2K1C and sham-clipped group and didn't alter after unclipping ( $p > 0.05$ ).

#### Discussion

Endothelium is an early target of cardiovascular risk factors such as hypertension. Endothelial dysfunction is characterized by changes in endothelial permeability, endothelium-derived factors and vasomotor responses. Among the endothelium-derived vasoactive factors, NO is one of the most well characterized. In this study, we found that serum NO concentrations in 2K1C hypertensive rats were lower than sham-clipped group. Impaired endothelium-dependent relaxation indicated in all models of hypertension including 2K1C (Luscher and Vanhoutte 1986; Nakamura and Prewitt 1992) and in human hypertension (Linder et al. 1990). In this study, we measured serum NO level after 12 weeks induction of hypertension. It is indicated that after renal artery clipping, NO synthesis increases during two weeks and then gradually declines during next weeks (Dubey et al. 1996). The later decrease in serum NO level could be the result of either endothelial dysfunction due to hypertension or adaptation to high blood pressure. NO has several beneficial role in vascular homeostasis including vascular tone, control of blood pressure and antiatherosclerotic properties (Bian et al. 2008; Pepine 2009) and decreased NO bioavailability could explain why cardiovascular risk factors such as

hypertension are considered risk factor for atherosclerosis. NO also affect endothelial permeability in different tissues, although there are contradictory reports (Filep and Foldes-Filep 1993; Yuan et al. 1993). Some studies reported that NO synthase inhibitor increased microvascular permeability in stomach, intestine, liver, spleen, pancreas, kidney, and lung (Filep and Foldes-Filep 1993) whereas in other studies, NO inhibitor decreased microvascular permeability of venules (Yuan et al. 1993).

Decreased NO bioavailability in hypertensive subjects may results from lower NO production such as deficiency in L-arginine/BH4 (Cosentino and Luscher 1999; Zhou et al. 2001) or increased NO degradation due to higher superoxide anion generation or reduced level of antioxidant (Schulman et al. 2005). Furthermore, 2K1C goldblatt model induces renin-angiotensin dependent hypertension and another explanation for reduced NO availability in this model of hypertension is that high angiotensin II level decreases NO bioavailability by promoting oxidative stress (de Gasparo 2002).

We also found that surgical reversal of hypertension did not improve serum NO concentration while blood pressure reached to normotensive level. In agreement to our results, a study in renovascular hypertensive rats revealed that production of NO partly contributes to blood pressure reduction after unclipping (Huang and Tsai 1998). Thus, it seems that in addition to NO, other mechanisms could be involved in surgical reversal of hypertension.

The barrier function of endothelium and control of its permeability that regulates macromolecular transport is a key defense mechanism against vascular injury and atherosclerosis (van Hinsbergh 1997; De Caterina 2000). In addition, recent studies suggested that increased vascular endothelial permeability have a role in development of end organ damage during hypertension (Viazzi et al. 2008). Thus, in this study, we expected higher endothelial permeability in 2K1C hypertensive group compare to sham animals. However, we did not find any difference in endothelial permeability between these groups. It seems that elevated blood pressure and disruption of the starling equilibrium could increase endothelial permeability (Parving and Gyntelberg 1973); however, in this study, preservation of endothelial permeability in 2K1C hypertensive group indicated that change of hemodynamic forces in hypertension does not contribute in endothelial permeability (Pedrinelli et al. 1999). In agreement to our results, a recent clinical study evaluated systemic capillary permeability using TERalb (another parameter for estimation of capillary permeability) and found that systemic capillary permeability was not different between normotensive and hypertensive group (Dell'Omo et al. 2004). In another study, TERalb was higher in atherosclerotic patients, however, was not different between normotensive and hypertensive subjects (Pedrinelli et al. 1998). In contrast, another study demonstrated that

**Table 2.** Quantitative extravasations of aorta and heart Evans blue (EB)

	Group	<i>n</i>	Aorta EB ( $\mu\text{g/g ww}$ )	Heart EB ( $\mu\text{g/g ww}$ )
Post-clipping	Sham	7	33.72 $\pm$ 3.58	17.62 $\pm$ 1.40
	2K1C	7	24.58 $\pm$ 1.62	12.57 $\pm$ 1.65
Unclipping	Sham	7	32.94 $\pm$ 6.19	14.19 $\pm$ 3.68
	2K1C	7	25.84 $\pm$ 3.89	15.95 $\pm$ 1.76

Data are expressed as mean  $\pm$  S.E. ww, wet weight.

endothelial permeability was higher in hypertensive subjects, but endothelium-dependent relaxation was not different in uncomplicated mild to moderate hypertension (Paulis et al. 2008). We also found that reversal of hypertension did not alter endothelial permeability. Although, we do not have direct information about the vascular structural changes, it have been already shown that permeability of both media and endothelium are changed during hypertension (Kennedy and Tedgui 1995). It's suggested that changes in vascular structure during hypertension is adaptive, rather than causal (Panza et al. 1993).

In conclusion, lower serum NO concentration in 2K1C hypertensive rats even after surgical reversal of hypertension suggested that in addition to NO, other mechanisms such as bradykinin, histamine or other endothelium-derived releasing factors could be involved in surgical reversal of hypertension. Also, hypertension did not significantly change coronary vascular and aortic endothelial permeability and reversal of high blood pressure did not alter endothelial permeability.

**Acknowledgment.** This study was supported by Isfahan University of Medical Sciences (grant No. 187008).

## References

- Bauer V., Sotnikova R. (2010): Nitric oxide – the endothelium-derived relaxing factor and its role in endothelial functions. *Gen. Physiol. Biophys.* **29**, 319–340  
doi:10.4149/gpb\_2010\_04\_319
- Bian K., Doursout M. F., Murad F. (2008): Vascular system: role of nitric oxide in cardiovascular diseases. *J. Clin. Hypertens. (Greenwich.)* **10**, 304–310  
doi:10.1111/j.1751-7176.2008.06632.x
- Cosentino F., Luscher T. F. (1999): Tetrahydrobiopterin and endothelial nitric oxide synthase activity. *Cardiovasc. Res.* **43**, 274–278  
doi:10.1016/S0008-6363(99)00134-0
- De Caterina R. (2000): Endothelial dysfunctions: common denominators in vascular disease. *Curr. Opin. Clin. Nutr. Metab. Care* **3**, 453–467  
doi:10.1097/00075197-200011000-00007
- de Gasparo M. 2002: Angiotensin II and nitric oxide interaction. *Heart Fail. Rev.* **7**, 347–358  
doi:10.1023/A:1020714518246
- Dell’Omo G., Penno G., Pucci L., Mariani M., Del Prato S., Pedrinelli R. (2004): Abnormal capillary permeability and endothelial dysfunction in hypertension with comorbid Metabolic Syndrome Atherosclerosis **172**, 383–389
- Diekmann F., Zart R., Thone-Reineke C., Bauer C., Neumayer H. H., Hoher B. (2000): Regulation of the renal endothelin system in the two-kidney, one clip renal hypertensive rat. *J. Cardiovasc. Pharmacol.* **36**, S191–194
- Dubey R. K., Boegehold M. A., Gillespie D. G., Rosselli M. (1996): Increased nitric oxide activity in early renovascular hypertension. *Am. J. Physiol.* **270**, R118–124
- Feletou M., Vanhoutte P. M. (2006): Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture). *Am. J. Physiol. Heart Circ. Physiol.* **291**, H985–1002  
doi:10.1152/ajpheart.00292.2006
- Filep J. G., Foldes-Filep E. (1993): Modulation by nitric oxide of platelet-activating factor-induced albumin extravasation in the conscious rat. *Br. J. Pharmacol.* **110**, 1347–1352
- Hermann M., Flammer A., Luscher T. F. (2006): Nitric oxide in hypertension. *J. Clin. Hypertens. (Greenwich.)* **8**, 17–29  
doi:10.1111/j.1524-6175.2006.06032.x
- Huang W. C., Tsai R. Y. (1998): Nitric oxide synthesis inhibition retards surgical reversal of one-kidney Goldblatt hypertension in rats. *Hypertension* **32**, 534–540
- Hulthen U. L., Cao Z., Rumble J. R., Cooper M. E., Johnston C. I. (1996): Vascular hypertrophy and albumin permeability in a rat model combining hypertension and diabetes mellitus. Effects of calcium antagonism, angiotensin converting enzyme inhibition, and angiotensin II-AT1-receptor blockade. *Am. J. Hypertens.* **9**, 895–901  
doi:10.1016/S0895-7061(96)00177-X
- Kawashima S., Yokoyama M. (2004): Dysfunction of endothelial nitric oxide synthase and atherosclerosis. *Arterioscler. Thromb. Vasc. Biol.* **24**, 998–1005  
doi:10.1161/01.ATV.0000125114.88079.96
- Kennedy J. H., Tedgui A. (1995): Normal and pathological aspects of mass transport across the vascular wall. *Cardiovasc. Surg.* **3**, 611–615  
doi:10.1016/0967-2109(96)82858-4
- Khazaei M., Moien-Afshari F., Laher I. (2008): Vascular endothelial function in health and diseases. *Pathophysiology* **15**, 49–67  
doi:10.1016/j.pathophys.2008.02.002
- Khazaei M., Nematbakhsh M. (2004): Coronary vascular and aortic endothelial permeability during estrogen therapy: a study in DOCA-salt hypertensive ovariectomized rats. *Physiol. Res.* **53**, 609–614
- Khazaei M., Nematbakhsh M. (2006): The effect of hypertension on serum nitric oxide and vascular endothelial growth factor concentrations. A study in DOCA-Salt hypertensive ovariectomized rats. *Regul. Pept.* **135**, 91–94  
doi:10.1016/j.regpep.2006.04.003
- Kunes J. (1993): The influence of age on the development of two-kidney, one-clip hypertension in the rat. *Physiol. Res.* **42**, 205–208
- Linder L., Kiowski W., Buhler F. R., Luscher T. F. (1990): Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension. *Circulation* **81**, 1762–1767
- Luscher T. F. (1994): The endothelium and cardiovascular disease--a complex relation. *N. Engl. J. Med.* **330**, 1081–1083  
doi:10.1056/NEJM199404143301511
- Luscher T. F., Vanhoutte P. M. (1986): Endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat. *Hypertension* **8**, 344–348
- Martinez-Maldonado M. (1991): Pathophysiology of renovascular hypertension. *Hypertension* **17**, 707–719
- Nakamura T., Prewitt R. L. (1992): Alteration of endothelial function in arterioles of renal hypertensive rats at two levels of vascular tone. *J. Hypertens.* **10**, 621–627

- doi:10.1097/00004872-199207000-00004
- Nystrom H. C., Jia J., Johansson M., Lambert G., Bergstrom G. (2002): Neurohormonal influences on maintenance and reversal of two-kidney one-clip renal hypertension. *Acta Physiol. Scand.* **175**, 245–251  
doi:10.1046/j.1365-201X.2002.00997.x
- Panza J. A., Quyyumi A. A., Callahan T. S., Epstein S. E. (1993): Effect of antihypertensive treatment on endothelium-dependent vascular relaxation in patients with essential hypertension. *J. Am. Coll. Cardiol.* **21**, 1145–1151  
doi:10.1016/0735-1097(93)90238-V
- Parving H. P., Gynzelberg F. (1973): Transcapillary escape rate of albumin and plasma volume in essential hypertension. *Circ. Res.* **32**, 643–651
- Paulis L., Matuskova J., Adamcova M., Pelouch V., Simko J., Krcijirovicova K., Potacova A., Hulin I., Janega P., Pechanova O., Simko F. (2008): Regression of left ventricular hypertrophy and aortic remodelling in NO-deficient hypertensive rats: effect of L-arginine and spironolactone. *Acta Physiol. (Oxf.)* **194**, 45–55  
doi:10.1111/j.1748-1716.2008.01862.x
- Pedrinelli R., Penno G., Dell’Omo G., Bandinelli S., Giorgi D., Di B., V, Nannipieri M., Navalesi R., Mariani M. (1998): Transvascular and urinary leakage of albumin in atherosclerotic and hypertensive men. *Hypertension* **32**, 318–323
- Pedrinelli R., Penno G., Dell’Omo G., Bandinelli S., Giorgi D., Di B., V, Navalesi R., Mariani M. (1999): Microalbuminuria and transcapillary albumin leakage in essential hypertension. *Hypertension* **34**, 491–495
- Pepine C. J. (2009): The impact of nitric oxide in cardiovascular medicine: untapped potential utility. *Am. J. Med.* **122**, S10–15  
doi:10.1016/j.amjmed.2009.03.003
- Ross R. (1993): The pathogenesis of atherosclerosis: a perspective for the 1990s. *Nature* **362**, 801–809  
doi:10.1038/362801a0
- Ross R. (1999): Atherosclerosis--an inflammatory disease. *N.Engl. J. Med.* **340**, 115–126  
doi:10.1056/NEJM199901143400207
- Schulman I. H., Zhou M. S., Raj L. (2005): Nitric oxide, angiotensin II, and reactive oxygen species in hypertension and atherogenesis. *Curr. Hypertens. Rep.* **7**, 61–67  
doi:10.1007/s11906-005-0056-6
- Torok J. (2008): Participation of nitric oxide in different models of experimental hypertension. *Physiol. Res.* **57**, 813–825
- van Hinsbergh W. M. (1997): Endothelial permeability for macromolecules. Mechanistic aspects of pathophysiological modulation. *Arterioscler. Thromb. Vasc. Biol.* **17**, 1018–1023
- Versari D., Daghini E., Virdis A., Ghiadoni L., Taddei S. (2009): Endothelial dysfunction as a target for prevention of cardiovascular disease. *Diabetes Care* **32** (Suppl. 2), S314–321  
doi:10.2337/dc09-S330
- Viazzi F., Leoncini G., Ratto E., Parodi A., Falqui V., Conti N., Tomolillo C., Ravera G., Deferrari G., Pontremoli R. (2008): Vascular permeability, blood pressure, and organ damage in primary hypertension. *Hypertens. Res.* **31**, 873–879  
doi:10.1291/hypres.31.873
- Yuan Y., Granger H. J., Zawieja D. C., DeFily D. V., Chilian W. M. (1993): Histamine increases venular permeability via a phospholipase C-NO synthase-guanylate cyclase cascade. *Am. J. Physiol.* **264**, H1734–1739
- Zhou M. S., Kosaka H., Tian R. X., Abe Y., Chen Q. H., Yoneyama H., Yamamoto A., Zhang L. (2001): L-Arginine improves endothelial function in renal artery of hypertensive Dahl rats. *J. Hypertens.* **19**, 421–429  
doi:10.1097/00004872-200103000-00010

Received: October 5, 2010

Final version accepted: January 24, 2011